Physician profile
Steve Simpson
NPI 1730172958
$4,184.18
in general payments reported to CMS, 2019-2025
50 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $312 · 2021: $709 · 2022: $837 · 2023: $914 · 2024: $392 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,017.52 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $363.00 | 2019-2025 | |
| Amgen INC. | $296.12 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $256.22 | 2019-2023 | Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $247.64 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $167.96 | 2019-2024 | Mounjaro |
| Biohaven Pharmaceuticals, INC. | $159.92 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.41 | 2019-2024 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $131.17 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $120.70 | 2022-2025 | Spravato |
| Novo Nordisk INC | $94.32 | 2021-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.05 | 2019-2021 | |
| Bausch Health US, LLC | $92.64 | 2019-2022 | |
| Astellas Pharma US INC | $82.42 | 2019-2024 | Veozah |
| Dexcom, INC. | $72.27 | 2021-2023 | Dexcom G6 Transmitter |
Show all 47 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.